Alfuzosin is an α1-adrenergic receptor antagonist that is used clinically to treat benign prostatic hyperplasia (BPH); it relaxes prostatic smooth muscle and increases the urinary flow rate. Alfuzosin also delays cardiac repolarization by increasing the Na+ current. This compound prolongs action potential duration and the QT interval in vivo by increasing the probability of hNa(v)1.5 channel openings and burst duration.
| Cas No. | 81403-68-1 |
|---|---|
| Purity | ≥98% |
| Formula | C19H27N5O4 • HCl |
| Formula Wt. | 425.91 |
| Chemical Name | (2RS)-N-[3-[(4-Amino-6, 7-dimethoxyquinazolin-2-yl)methylamino]propyl]tetrahydrofuran-2-carboxamide hydrochloride |
| IUPAC Name | N-[3-[(4-amino-6,7-dimethoxyquinazolin-2-yl)-methylamino]propyl]oxolane-2-carboxamide;hydrochloride |
| Melting Point | 229-231C |
| Appearance | White to off white powder Crystalline |
| Store Temp | Ambient |
|---|---|
| Ship Temp | Ambient |
| MSDS | A4523 MSDS PDF |
|---|---|
| Info Sheet | A4523 Info Sheet PDF |
Lacerda AE, Kuryshev YA, Chen Y, et al. Alfuzosin delays cardiac repolarization by a novel mechanism. J Pharmacol Exp Ther. 2008 Feb;324(2):427-33. PMID: 17986649.
Lee M. Alfuzosin hydrochloride for the treatment of benign prostatic hyperplasia. Am J Health Syst Pharm. 2003 Jul 15;60(14):1426-39. Erratum in: Am J Health Syst Pharm. 2004 Mar 1;61(5):437. PMID: 12892027.
Dutkiewics S. Efficacy and tolerability of drugs for treatment of benign prostatic hyperplasia. Int Urol Nephrol. 2001;32(3):423-32. PMID: 11583366.
